echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A new generation of antibody-coupled drugs is eligible for FDA priority review

    A new generation of antibody-coupled drugs is eligible for FDA priority review

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bladder cancer is one of the most common types of cancer, with about 80% of patients in NMIBC.
    in these diseases, cancer cells are located in the bladder or have developed into the inner cavity of the bladder, but have not yet spread to muscles or other tissues.
    NMIBC mainly affects men and is associated with exposure to carcinogens.
    patients undergoing initial surgical excision have a high recurrence rate, and more than 60% of patients will receive BCG immunotherapy.
    BCG is effective in many patients, tolerance problems have been observed and many patients experience a recurrence of the disease.
    if BCG is ineffective or if the patient needs to receive BCG for a long time, the recommended treatment is a complete removal of the bladder.
    Vicineum is a next-generation ADC drug developed using Sesen Bio's proprietary targeted protein therapy platform.
    it connects the antibody fragments of EpCAM, which targets the surface of tumor cells, to the cytotoxic loaded protobacterial extratoxin A (ETA) through stable genetically engineered peptides.
    expressed at a high level on the surface of NMIBC cells, but at very low or non-expression levels in normal cells.
    advantage of this ADC is that it has a small molecular weight and can promote tumor penetration and drug delivery.
    it has a dual mechanism that, in addition to targeting tumor cells through cytotoxic loads, can activate T-cell-mediated anti-cancer immune responses.
    previously published clinical data show that after three months of treatment, the rate of complete remission (CRR) in patients with high-risk NMIBC in-place cancer (CIS) reached 40%, and the rate of non-recurrence of NMIBC papicular cancer reached 71%.
    76% of patients do not need to have their bladder completely removed within three years.
    Sesen Bio said it expected to submit regulatory applications to the EU over the next 1-2 months.
    , Qilu Pharmaceuticals is expected to announce the latest developments in Vicineum's IND application in China.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    resources: sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for vicinity ™. Retrieved February 16, 2021, from [2] Seseon Bio, January business update. Retrieved February 16, 2021, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.